QbDVision

About QbDVision

QbDVision, founded in 2017 and headquartered in Austin, Texas, provides a digital platform for the life sciences industry focused on Chemistry, Manufacturing, and Controls (CMC). The company, formerly known as CherryCircle Software, was co-founded by Yash Sabharwal (CEO) and Ryan Shillington (CTO). Sabharwal, a serial entrepreneur with a Ph.D. in Optical Sciences, identified the need for a modern software solution while serving as COO at Xeris Pharmaceuticals. He experienced firsthand the inefficiencies of managing complex drug development with spreadsheets and documents, which led him to partner with his neighbor, Shillington, a seasoned software architect, to create a solution.

The firm operates on a Software-as-a-Service (SaaS) business model, providing a cloud-based platform to pharmaceutical and biotech companies. Its client base includes a range of organizations from biotech startups to large enterprise pharma companies, including three of the top six global pharma and biotech firms. QbDVision's platform is designed to digitize and centralize the entire product lifecycle management process, moving teams away from siloed, document-centric workflows. It enables users to organize unstructured data, automate workflows like technology transfer, and enhance collaboration across teams and functions. The system provides a structured framework that connects product information, processes, and personnel, offering a single source of truth for development and manufacturing.

The core product, the Digital CMC Platform, is purpose-built to help biopharma organizations accelerate the development of therapies as they transition from R&D to commercial manufacturing. It offers tools for centralized knowledge management, streamlined process development, and process intelligence, allowing teams to see how actions impact the entire product lifecycle. Key features include activity logging, version control, and audit trails to ensure data integrity and compliance, which is critical for regulatory submissions to bodies like the FDA. By structuring and contextualizing CMC data, the platform aims to reduce cycle times, mitigate quality risks, and prepare companies for a future where AI-driven methods are more prevalent in drug manufacturing.